Authors:
Kita, T
Tanigawara, Y
Chikazawa, S
Hatanaka, H
Sakaeda, T
Komada, F
Iwakawa, S
Okumura, K
Citation: T. Kita et al., N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients, BIOL PHAR B, 24(5), 2001, pp. 544-549
Authors:
Minami, H
Ohtsu, T
Fujii, H
Igarashi, T
Itoh, K
Uchiyama-Kokubu, N
Aizawa, T
Watanabe, T
Uda, Y
Tanigawara, Y
Sasaki, Y
Citation: H. Minami et al., Phase I study of intravenous PSC-833 and doxorubicin: Reversal of multidrug resistance, JPN J CANC, 92(2), 2001, pp. 220-230
Authors:
Sakai, T
Aoyama, N
Kita, T
Sakaeda, T
Nishiguchi, K
Nishitora, Y
Hohda, T
Sirasaka, D
Tamura, T
Tanigawara, Y
Kasuga, M
Okumura, K
Citation: T. Sakai et al., CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects, PHARM RES, 18(6), 2001, pp. 721-727
Authors:
Kita, T
Tanigawara, Y
Aoyama, N
Hohda, T
Saijoh, Y
Komada, F
Sakaeda, T
Okumura, K
Sakai, T
Kasuga, M
Citation: T. Kita et al., CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability, PHARM RES, 18(5), 2001, pp. 615-621
Authors:
Takama, H
Tanaka, H
Sudo, T
Tamura, T
Tanigawara, Y
Citation: H. Takama et al., Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study, CANC CHEMOT, 47(5), 2001, pp. 404-410
Authors:
Tanigawara, Y
Kita, T
Hirono, M
Sakaeda, T
Komada, F
Okumura, K
Citation: Y. Tanigawara et al., Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood, THER DRUG M, 23(4), 2001, pp. 341-346
Authors:
Takara, K
Tanigawara, Y
Komada, F
Nishiguchi, K
Sakaeda, T
Okumura, K
Citation: K. Takara et al., The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein, JPN J CANC, 91(2), 2000, pp. 248-254
Authors:
Aoyama, N
Tanigawara, Y
Kita, T
Sakai, T
Shirakawa, K
Shirasaka, D
Kodama, F
Okumura, K
Kasuga, M
Citation: N. Aoyama et al., Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P4502C19 poor metabolizers, J GASTRO, 34, 1999, pp. 80-83
Authors:
Komada, F
Nishiguchi, K
Tanigawara, Y
Iwakawa, S
Okumura, K
Citation: F. Komada et al., Effects of secretable SOD delivered by genetically modified cells on xanthine/xanthine oxidase and paraquat-induced cytotoxicity in vitro, BIOL PHAR B, 22(8), 1999, pp. 846-853
Authors:
Takara, K
Tanigawara, Y
Komada, F
Nishiguchi, K
Sakaeda, T
Okumura, K
Citation: K. Takara et al., Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs, BIOL PHAR B, 22(12), 1999, pp. 1355-1359
Authors:
Tagawa, Y
Miwa, K
Yamashita, K
Tsukuda, R
Yoshimura, Y
Tanayama, S
Tanigawara, Y
Citation: Y. Tagawa et al., Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats, BIOPHARM DR, 20(1), 1999, pp. 11-18
Authors:
Tagawa, Y
Miwa, K
Tsukuda, R
Yoshimura, Y
Tanayama, S
Tanigawara, Y
Citation: Y. Tagawa et al., Effect of its demethylated metabolite on the pharmacokinetics of unchangedTAK-603, a new antirheumatic agent, in rats, DRUG META D, 27(4), 1999, pp. 495-501
Authors:
Tanigawara, Y
Aoyama, N
Kita, T
Shirakawa, K
Komada, F
Kasuga, M
Okumura, K
Citation: Y. Tanigawara et al., CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori, CLIN PHARM, 66(5), 1999, pp. 528-534
Authors:
Nishiguchi, K
Komada, F
Tanigawara, Y
Sakai, Y
Iwakawa, S
Okumura, K
Citation: K. Nishiguchi et al., Effects of Cu,Zn-superoxide dismutase delivered by genetically modified skin fibroblasts on cold-induced skin edema in rats, BIOL PHAR B, 21(12), 1998, pp. 1379-1381
Authors:
Kusunoki, N
Takara, K
Tanigawara, Y
Yamauchi, A
Ueda, K
Komada, F
Ku, Y
Kuroda, Y
Saitoh, Y
Okumura, K
Citation: N. Kusunoki et al., Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein, JPN J CANC, 89(11), 1998, pp. 1220-1228